Do Weight-Management Medications Hold Up Long Term? Reading the Maintenance Data

A lot of the conversation around weight-loss medications treats them like a course of antibiotics: take it for a while, finish the plan, keep the result. The trial data tells a different story. Several controlled studies have tracked what happens when people stop taking a GLP-1 medication after losing weight on it, and the pattern is consistent enough to matter before anyone starts.

What the trials actually tested

The clearest evidence comes from a 2021 trial published in JAMA. Researchers put 902 adults with overweight or obesity on semaglutide 2.4 mg weekly for 20 weeks, then randomized the 803 who reached target dose into two groups: one kept taking semaglutide, the other switched to a placebo, for another 48 weeks. Both groups got the same lifestyle counseling.

The difference showed up fast. From week 20 to week 68, the group that stayed on semaglutide lost another 7.9% of their body weight on average. The group switched to placebo gained back 6.9%. That's a 14.8 percentage point gap between the two groups, and it opened up in under a year. Both groups started from the same place, had lost the same amount of weight during the run-in, and got the same lifestyle counseling afterward. The only variable that changed was whether the medication kept going.

The researchers behind the trial noted a limit worth carrying forward: because everyone in the study had already shown they tolerated semaglutide well during the run-in period, the results likely represent a best-case scenario rather than what happens across a broader, less-selected population.

A separate extension of an earlier trial followed people even further, watching what happened after they stopped the medication entirely rather than switching to placebo mid-study. Participants had lost 17.3% of their body weight over 68 weeks on semaglutide. Over the next 52 weeks off the drug, they regained 11.6 percentage points of that, roughly two-thirds of what they'd lost. Some of the metabolic improvements from treatment (blood pressure, most cholesterol markers) drifted back toward baseline too, though a few measures stayed modestly better than the placebo group's.

The regain has a shape, not just a size

One study on its own could be an outlier. A 2026 systematic review in eClinicalMedicine pooled data across multiple trials to see whether the regain pattern held up more broadly. Using six randomized trials with a combined 3,236 participants, the researchers modeled how weight came back after people stopped a GLP-1 medication.

The pattern: regain happens fastest in the first months after stopping, then slows down. The researchers calculated a half-life of about 23 weeks for the regain curve, meaning the return toward baseline weight is quickest early on and gradually tapers rather than continuing at a constant rate. By one year post-cessation, the model found that people had regained about 60% of the weight they'd lost on treatment. Projecting further out, the researchers estimated regain eventually levels off, though still well above the treated weight, meaning some benefit may persist longer term even after most of it fades. The exact pace varied across the studies included, which is part of why the researchers described a general trajectory rather than a single fixed number, and they were upfront that anything past the 52 weeks of actual observed data is a projection, not a measurement.

None of this means the medications don't work. The same trials show large weight loss while treatment continues. What they also show is that the loss is tied to the treatment continuing, in both of the designs that tested it: the withdrawal trial where one group switched to placebo, and the extension where everyone came off. "Maintenance" in that data refers to staying on treatment, not to finishing a course and keeping the result afterward.

Where the data runs out

Every trial above ran on FDA-approved, branded GLP-1 medications at studied doses, and the first two ran on one branded formulation of semaglutide. That's worth being direct about, because a lot of what's marketed for weight loss and longevity right now isn't that. Compounded versions of semaglutide or tirzepatide are not FDA-approved products, and neither they nor the broader category of peptides sold for weight management or anti-aging purposes have gone through the same kind of long-term, randomized, placebo-controlled testing. There's no equivalent trial showing what a maintenance or discontinuation curve looks like for those products, because that research doesn't exist yet. Reasoning from one to the other, assuming the same trajectory applies, is not something the current evidence supports.

That gap matters for anyone deciding what "long-term" is supposed to mean for a specific product. Reading what the actual studies measured, including how they were designed and what they left out, is a better starting point than assuming any weight-management product will hold its results indefinitely. The peptide guide collection walks through how to read these kinds of long-term evidence claims across weight and longevity programs, including where compounded and branded products differ in what's actually been studied.

What the data can and can't settle

If someone is already using a GLP-1 medication, weighing whether to continue, or looking at telehealth access to one, this data doesn't answer the personal question of what to do next. That one belongs with a licensed clinician who knows the person's history. What it does narrow is what "long term" can honestly mean in a marketing sentence: continued treatment is what the trials measured, not a finite course. Anyone comparing programs, including the System Labs telehealth platform, can read the trial designs above first and then ask plainly what a program covers over time and what it costs.

Sources

• Wilding et al., STEP 4, JAMA 2021. https://jamanetwork.com/journals/jama/fullarticle/2777886. 803 adults with overweight/obesity who reached target dose in a 20-week run-in, randomized to continue semaglutide 2.4 mg weekly or switch to placebo for 48 weeks. Weight change from week 20 to week 68 was minus 7.9% (continued) versus plus 6.9% (placebo). Limitation: the run-in selects for people who tolerate the drug, and the design tests a 48-week switch, not indefinite discontinuation.
• Wilding et al., STEP 1 trial extension, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/. 327 participants from the original STEP 1 cohort, full treatment withdrawal followed for 52 additional weeks. Regained roughly two-thirds of prior weight loss (11.6 of 17.3 percentage points), with partial reversal of cardiometabolic improvements. Limitation: a smaller, self-selected follow-up sample with exploratory, not confirmatory, analysis.
• Systematic review and nonlinear meta-regression, eClinicalMedicine, 2026. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00043-X/fulltext. Six randomized trials, 3,236 participants, pooled post-cessation data. Found 60% of on-treatment weight loss regained by one year, with a modeled longer-term plateau. Limitation: the plateau estimate beyond 52 weeks is an extrapolation, and pace varied across the studies included.
• FDA, Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers. Agency explainer covering compounded drug products from 503A pharmacies and 503B outsourcing facilities. States that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before they are marketed. Limitation: not a review of any specific product and not evidence about long-term weight outcomes.

Educational content only. Not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, changing, or stopping any medication, peptide, or supplement.